---
title: "ALT: Pemvidutide met key efficacy endpoints in AUD, reducing heavy drinking and increasing abstinence"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294057380.md"
description: "Pemvidutide significantly reduced heavy drinking days, increased abstinence, and improved key FDA-recognized endpoints in adults with AUD and overweight/obesity. The drug also promoted weight loss and showed a generally favorable safety profile, supporting further development.Original document: Altimmune, Inc. [ALT] Slides Release — Jul. 28 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-28T11:21:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294057380.md)
  - [en](https://longbridge.com/en/news/294057380.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294057380.md)
generator: "portal-rs"
---

# ALT: Pemvidutide met key efficacy endpoints in AUD, reducing heavy drinking and increasing abstinence

Pemvidutide significantly reduced heavy drinking days, increased abstinence, and improved key FDA-recognized endpoints in adults with AUD and overweight/obesity. The drug also promoted weight loss and showed a generally favorable safety profile, supporting further development.

Original document: Altimmune, Inc. \[ALT\] Slides Release — Jul. 28 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ALT.US](https://longbridge.com/en/quote/ALT.US.md)

## Related News & Research

- [Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial](https://longbridge.com/en/news/294079208.md)
- [Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD](https://longbridge.com/en/news/294056102.md)
- [CSW.A: Record revenue, earnings, and RTD growth, with higher dividends and renewed Pernod Ricard partnership](https://longbridge.com/en/news/297236757.md)
- [Moleculin highlights interim data from pivotal MIRACLE Phase 2/3 Annamycin trial in relapsed/refractory AML](https://longbridge.com/en/news/297191000.md)
- [Endovia plans FDA pre-submission conference for CannEpil Z filing](https://longbridge.com/en/news/297517810.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**